FATE News and Press, Fate Therapeutics Inc. From 08/07/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks with lower market capitalizations ranging from $300 million to $2 billion have taken quite a hit since January. These stocks typically belong to smaller companies with massive long-term growth potential. Ho...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...

Fate Therapeutics Inc. (FATE) Q2 2022 Earnings Conference Call August 03, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of Ame...

Fate Therapeutics press release ( NASDAQ: FATE ): Q2 GAAP EPS of -$0.79 beats by $0.04 . Collaboration Revenue of $18.55M (+38.3% Y/Y) beats by $5.99M . Cash, cash equivalents and investments as of June 30, 2022 were $580.8 million. For further details se...

FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL FT516 RMAT Meeting Scheduled with FDA for 3Q22 to Discuss Registrational Pathways for R/R BCL ...

Needham has initiated coverage on Fate Therapeutics ( NASDAQ: FATE ) with a hold rating citing the potential of its stem cell cancer therapies. Fate develops induced pluripotent stem cell (iPSC) derived cancer therapeutics, primarily NK cells, which can address several cha...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing. However, after skyrocketing i...

SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cance...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. From 1/2/2016 to date, investing in all 50 stocks, equally weighted, would have produced a total return of 84.7%, a...

The recent stock rally has made some crowded shorts more squeezable, according to S3 Partners' Ihor Dusaniswky. Dusaniswky created a ranking of the most crowded shorts based on factors like total short dollars at risk, short interest as a true percentage of a company's tradable floa...